Sirs, Although restless legs syndrome (RLS) is a common cause of sleep disruption and the prevalence of this condition in primary care is high (15-25%) [1] , most physicians have remained unaware of the disorder. As a consequence, many patients have remained undiagnosed or misdiagnosed and have not been managed adequately, resulting in a subsequent negative impact on sleep and quality of life [2] [3] [4] . The clinical diagnostic criteria for RLS are: (1) the patient must have an urge to move his/her legs; (2) symptoms must be aggravated by rest; (3) symptoms must be alleviated by movement, especially by walking; (4) symptoms must be worse in the evening or night (circadian rhythm) [4, 5] . This syndrome may be the result of abnormalities of the dopamine and iron systems, and the role of these systems in RLS pathophysiology has been supported by therapeutic benefits, although these relationships are not fully understood [6] [7] [8] .
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A 45-year-old woman, with no past medical history, was diagnosed with major a depressive disorder and prescribed 5 mg olanzapine and 5 mg aripiprazole daily. After 10 months, the olanzapine was discontinued and the dose of aripiprazole increased to 15 mg daily. Her depressive symptoms improved, but a few days after the increased dosage of aripiprazol had been initiated, the patient presented with an unpleasant aching sensation in both legs characterized by creeping and crawling feelings during the night that constantly interrupted her sleep. These symptoms appeared about 3-4 hours after she had taken her medication. She had no sudden involuntary muscle contractions, previous leg traumas, or akathisia. She was able to relieve the symptoms by moving her legs or by walking, and the symptoms were mild during the early morning. There was no history of caffeine intake or any other medication that may have exacerbated this condition.
Physical examination showed no abnormalities and no clinical signs of anemia; peripheral neuropathy or vascular diseases were not found. A diagnosis of RLS was made. Laboratory tests were performed to identify the secondary causes of the RLS (iron, ferritin, creatinine, blood urea nitrogen, thyroid hormones, glucose, and rheumatoid factor). All findings were normal. Even though aripiprazole was an effective therapy for her depressive symptoms, therapy with this drug was gradually discontinued, which resulted in disappearance of the RLS symptoms.
Dopamine agonists have been shown to be efficacious in the treatment of the RLS. This class of drugs directly stimulates dopamine receptors and has a longer half-life (4-6 h) than levodopa (90 min). Dopamine agonists are also generally superior to levodopa for the daily treatment of RLS. The mechanism by which these agents improve the symptoms of RLS is through the stimulation of dopamine D 2 receptors.
Aripiprazole and olanzapine are atypical antipsychotic drugs, acting as a partial agonist and antagonist, respectively, of the dopamine D 2 receptor. Aripiprazole has not been associated with RLS in other case reports [6] [7] [8] in which antidepressants and antipsychotics were found to induce RLS, and this is the first singularity that distinguishes this case. In theory, the difference in the mechanism of action may explain why RLS was not seen with aripiprazole. If antidepressants are necessary, the symptoms of secondary RLS can usually be treated in the same way as primary RLS [1] [2] [3] [4] . Bupropion is an alternative antidepressant that may be less likely to induce or worsen RLS [4, 5] .
Dopamine antagonists have been shown to exacerbate RLS, and the second singularity of this case is the absence of RLS associated with olanzapine, as has been reported previously [6, 7] , when the symptoms resolved after this drug was discontinued.
The third singularity is that RLS did not develop during the initial prescription of aripiprazole, appearing only when the dose had been increased. This observation suggests a probable dose-dependent appearance of RLS associated to aripiprazole. The classification of RLS is shown in Table 1 .
We suggest that future research should focus RLS induced by antipsychotic medication. 
